Publicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (53)

2024

  1. Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma

    Gastroenterology, Vol. 166, Núm. 5, pp. 886-901.e7

  2. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma

    Hepatology, Vol. 79, Núm. 4, pp. 941-958

  3. m6A Methylated Long Noncoding RNA LOC339803 Regulates Intestinal Inflammatory Response

    Advanced Science, Vol. 11, Núm. 13

2023

  1. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726

  2. Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation

    Gut

  3. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  4. Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma

    Cancers, Vol. 15, Núm. 20

2022

  1. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

    Hepatology, Vol. 76, Núm. 6, pp. 1617-1633

  2. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

    Cell Death and Disease, Vol. 12, Núm. 6

  2. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  3. Pathogenesis of Cholangiocarcinoma

    Annual Review of Pathology: Mechanisms of Disease, Vol. 16, pp. 433-463

  4. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

  5. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

    Gut, Vol. 70, Núm. 7, pp. 1345-1361

  6. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

    Cells, Vol. 9, Núm. 3

  3. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

  4. Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

    World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85

2019

  1. Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4–induced M2 macrophage polarization

    FASEB Journal, Vol. 33, Núm. 6, pp. 7578-7587